Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK rotavirus vaccine gets committee review

Executive Summary

GlaxoSmithKline's rotavirus vaccine Rotarix is scheduled for review by the Vaccines and Related Biological Products Advisory Committee Feb. 20. Over two consecutive seasons, Rotarix was more effective at preventing against rotavirus than Merck's RotaTeq, but GSK's vaccine fared worse at preventing severe cases. The product class has a history of safety concerns as well - Wyeth's RotaShield was withdrawn in 1999 due to safety concerns of intestinal blockage, and the label for Merck's RotaTeq was changed over incidence of intussusception as well in February 2007...

You may also be interested in...



FDA’s 2021 Budget Priorities For Cosmetics, Food Programs Include AI Use In Postmarket Oversight

FDA’s food, dietary supplement and cosmetics division seeks funding to support its artificial intelligence capabilities, including post-market surveillance and speedy interventions in instances where safety issues arise. Also of note, the agency cites UV filters’ effects on the skin microbiome as a research priority in its fiscal 2021 budget justification to Congress.

Don't Take For Granted A Patient's Role In Clinical Trials, Experts Say

Catering to patients can help make clinical trials more accessible and useful, presenters argued at a recent conference.

Warning Letter Roundup & Recap – 27 February 2020

In separate warning letters, the US FDA says Biomedix (a maker of I.V. administration sets) and Unetixs Vascular (a maker of vascular diagnostic ultrasound systems) must hire outside consultants to review their quality systems after serious deficiencies were noted by agency investigators. A total of three enforcement missives were released by the FDA this week.

UsernamePublicRestriction

Register

PS049260

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel